Infection

TUESDAY, MAY 23, 8:00AM-7:00PM

Allergy	Hematological Disorders	Patient-Reported Outcomes
Asthma	Infection	Skin
Cancer	Muscular-Skeletal Disorders	Smoking
Cardiovascular Disease	Osteoporosis	Surgery
Ear	Other	Health Care Use & Policy
Eye	Pain


Infection

PIN1	HEPATOTOXICITY ASSOCIATED WITH RIFAMPIN AND PYRAZINAMIDE THERAPY OF LATENT TUBERCULOSIS INFECTION: A META-ANALYSIS Ghosh S University of Louisiana at Monroe, Monroe, LA, USA

PIN2	COST COMPARISON OF A ONCE-DAILY PARENTERAL ANTIBIOTIC IN HOSPITAL SETTINGS: INFORMATION FROM THE SIDESTEP STUDY Turpin RS1, Tice A2, Wu JH1, Taylor S1, Polis A1, Abramson M1 1Merck & Co., Inc, West Point, PA, USA, 2University of Hawaii, Honolulu, HI, USA

PIN3	THE COST OF TREATING RIBAVIRIN-INDUCED ANEMIA IN HEPATITIS C: THE IMPACT OF USING RECOMBINANT HUMAN ERYTHROPOETIN Cross JT, Devine EB, Kowdley KV, Sullivan SD University of Washington, Seattle, WA, USA

PIN4	ECONOMIC ANALYSIS OF LATENT TUBERCULOSIS INFECTION (LTBI) SCREENING IN MILITARY RECRUITS: QUANTIFERON®-TB GOLD IN-TUBE (QFT-GIT) VERSUS TUBERCULIN SKIN TESTING (TST) Nevin R Army Medical Surveillance Activity, Washington, DC, USA

PIN5	Withdrawn

PIN6	COST-EFFECTIVENESS OF VORICONAZOLE VERSUS AMPHOTERICIN B DEOXICOLATE FOR THE PRIMARY TREATMENT OF INVASIVE ASPERGILLOSIS Aiello EC1, Devoto FM2, Dignani C3, De Vedia L4, Lorenzo H5 1Pfizer Argentina, Buenos Aires, Argentina, 2University of Buenos Aires, Buenos Aires, Argentina, 3Fundaleu, Buenos Aires, Argentina, 4Hospital Muñiz, Buenos Aires, Argentina, 5Pfizer Argentina, Buenos Aires, Argentina

PIN7	WITHDRAWN

PIN8	COST-EFFECTIVENESS OF LINEZOLID VERSUS VANCOMYCIN IN THE TREATMENT OF NOSOCOMIAL PNEUMONIA IN ARGENTINA Aiello EC1, Barcelona LI2, De Vedia L3, Stamboulian D2 1Pfizer Argentina, Buenos Aires, Argentina, 2FUNCEI, Buenos Aires, Argentina, 3Hospital Muñiz, Buenos Aires, Argentina

PIN9	ECONOMIC EVALUATION FOR THE ANTIMICROBIAL EMPIRIC TREATMENT OF HOSPITALIZED PATIENTS WITH VENTILATOR – ASSOCIATED PNEUMONIA DUE TO STAPHYLOCOCCUS AUREUS IN MEXICO Contreras-Hernandez I, Mould J, Suárez-Nuñez F, Garduño-Espinosa J Social Security Mexican Institute, Mexico City, Mexico

PIN10	COST EFFECTIVENESS OF TIPRANAVIR IN TREATMENT-EXPERIENCED HIV PATIENTS IN THE USA Simpson KN1, Chumney ECG1, Hicks CB2, Finnern H3 1Medical University of South Carolina, Charleston, SC, USA, 2Duke University Medical Center, Durham, NC, USA, 3Boehringer Ingelheim GmbH, Ingelheim, Germany

PIN11	THE IMPACT OF MECHANICAL VENTILATION ON OUTCOMES AND COSTS IN NOSOCOMIAL PNEUMONIA Neslusan C1, Nuyts G2, Stellhorn R1 1Johnson and Johnson Pharmaceutical Services, L.L.C, Raritan, NJ, USA, 2Johnson and Johnson, Raritan, NJ, USA

PIN12	LIFETIME MEDICAL COST OF CHRONIC HEPATITIS B Miriti MK, Billah K, Weinbaum C, Meltzer M Centers for Disease Control and Prevention, Atlanta, GA, USA

PIN13	COST OF THERAPY OF UPPER RESPIRATORY TRACT INFECTIONS IN A DEPRESSED ECONOMY Suleiman IA, Tayo F, Mendie U Faculty of Pharmacy, University of Lagos, Lagos, Nigeria

PIN14	DIRECT MEDICAL COSTS OF PATIENTS WITH HIV/AIDS IN MEXICO Contreras-Hernandez I1, Morales-Cisneros G1, Mould J1, Salinas-Escudero G1, Rely K2, Garduño-Espinosa J1 1Social Security Mexican Institute, Mexico City, Mexico, 2Pharmacoeconomic Consultor, Mexico City, Mexico

PIN15	THE EXPECTED ECONOMIC BURDEN OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) IN COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS (CSSSI) Mallick R1, Kuznik A1, Weber D2 1Wyeth Research, Collegeville, PA, USA, 2University of North Carolina, Chapel Hill, NC, USA

PIN16	CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA (CDAD) IN ACUTE HOSPITALS: A PREVALENT COST ISSUE O'Brien JA1, Pitoniak-Morse C1, Lahue BJ2, Davidson D2, Wilson D2, Caro JJ1 1Caro Research Institute, Concord, MA, USA, 2Genzyme Corporation, Cambridge, MA, USA

PIN17	A COST-UTILITY ANALYSIS OF PEGINTERFERON ALFA-2A VERSUS PEGINTERFERON ALFA-2B AS THE INITIAL TREATMENT OF HEPATITIS C FROM THE PERSPECTIVE OF THE VETERANS AFFAIRS HEALTH CARE SYSYTEM Yeh WS1, Armstrong EP2, Skrepnek GH2, Malone DC2 1University of North Carolina, Chapel Hill, NC, USA, 2University of Arizona, Tucson, AZ, USA

PIN18	HOSPITAL LENGTH-OF-STAY AND COSTS ASSOCIATED WITH USE AND EARLIER INITIATION OF DROTRECOGIN ALFA (ACTIVATED) IN ADULT PATIENTS WITH THE HIGHEST PROPENSITY OF HAVING SEVERE SEPSIS Ernst FR1, Viswanathan S2, Vedarajan G3, Reynolds J3, Kohli B3 1Eli Lilly and Company, Indianapolis, IN, USA, 2ZS Associates, Boston, MA, USA, 3ZS Associates, Evanston, IL, USA

PIN19	WITHDRAWN

PIN20	COMPARISON OF HEALTH OUTCOMES AMONG SEVERE COMMUNITY-ACQUIRED PNEUMONIA PATIENTS TREATED EMPIRICALLY WITH A BETA-LACTAM PLUS A MACROLIDE VERSUS A BETA-LACTAM PLUS A FLUOROQUINOLONE Frei CR1, Restrepo MI2, Mortensen EM3, Burgess DS4 1University of Texas at Austin and University of Texas Health Sci. Ctr. at San Antonio, San Antonio, TX, USA, 2University of Texas Health Sci. Ctr. at San Antonio, Vet. Evidence-Based Res. Dis. and Imp. Ctr, and South TX Health Care System, San Antonio, TX, USA, 3Univ. TX Health Sci. Ctr. at San Antonio, Vet. Evidence-Based Res. Dis. and Imp. Ctr, and South TX Health Care System, San Antonio, TX, USA, 4Univ. TX at Austin and Univ. TX Health Sci. Ctr. at San Antonio, San Antonio, TX, USA

PIN21	USE OF EVIDENCE BASED MODELS TO DEMONSTRATE THE LONG-TERM CLINICAL BENEFITS OF HPV VACCINATION. Bernard L1, Lindsay L2, Rogoza R1, Kohli MA1, Franco EL3 1Innovus Research Inc, Burlington, ON, Canada, 2GSK Biologicals, Rixensart, Belgium, 3McGill University, Montreal, QC, Canada

PIN22	USE OF PHARMACOKINETIC-PHARMACODYNAMIC MODELING WITH MONTE CARLO SIMULATION TO REDUCE ANTIBIOTIC EXPENDITURES WITHOUT COMPROMISING PREDICTED EFFICACY Frei CR1, Lewis JS2, Burgess DS1 1University of Texas at Austin and University of Texas Health Science Center at San Antonio, San Antonio, TX, USA, 2University of Texas at Austin and University of Texas Health Science Center at San Antonio and University Health System, San Antonio, TX, USA

PIN23	A REVIEW OF HERD EFFECTS IN THE ECONOMIC EVALUATION OF CHILDHOOD VACCINATIONS Vicente C1, McKinnon K1, Ciuryla V2, Han D1 1Wyeth Pharmaceuticals, Markham, ON, Canada, 2Wyeth Research, Collegeville, PA, USA

Contributed Posters Session I